Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UARK 2008-02: AS-CR in High-risk Myeloma
NCT00869232Phase 2Active, not recruiting
- Sponsor
- University of Arkansas
- Start
- Oct 2008
- Primary completion
- Oct 2027
- Modality
- Modified Peptides, DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib, melphalan, thalidomide, dexamethasone, cisplatin in multiple myeloma (MM), sponsored by University of Arkansas. Started Oct 2008; status: active, not recruiting.
02
Drugs
bortezomibmelphalanthalidomidedexamethasonecisplatin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00869232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00869232.